Dynavax Technologies (DVAX) - Stock & Dividends

Dynavax Technologies Corporation is a biopharmaceutical company that has reached commercial stage, focusing on developing and commercializing vaccines in the United States. Its main product, HEPLISAV-B, is a hepatitis B vaccine designed to prevent infection caused by all known subtypes of the hepatitis B virus in individuals aged 18 years and older. This vaccine is approved for use in both the United States and Europe.

In addition to HEPLISAV-B, the company also manufactures and sells CpG 1018, the adjuvant used in the vaccine. This adjuvant plays a crucial role in enhancing the immune response to the vaccine, making it more effective in preventing hepatitis B infection.

Dynavax Technologies Corporation has established collaborations with several prominent companies, including Valneva Scotland Limited, Zhejiang Clover Biopharmaceuticals, Inc., Clover Biopharmaceuticals (Hong Kong) Co., Limited, Biological E. Limited, PT Bio Farma, Medigen Vaccine Biologics, and Serum Institute of India Pvt. Ltd. These partnerships enable the company to expand its reach and accelerate the development of new vaccines.

The company, formerly known as Double Helix Corporation, was renamed Dynavax Technologies Corporation in September 1996. Since its incorporation in 1996, Dynavax Technologies Corporation has been headquartered in Emeryville, California, and has been committed to developing innovative vaccines to protect public health.

For more information about Dynavax Technologies Corporation and its vaccine development efforts, please visit their website at https://www.dynavax.com.